Jobs / United States / Astrazeneca Pharmaceuticals Lp
Executive Director, Search and Evaluation Oncology
Astrazeneca Pharmaceuticals Lp · 🇺🇸 2 Locations
Sponsorship verdict
Sponsorship possible
One solid signal, not two — worth applying, and worth asking about sponsorship early.
- Employer is on a government sponsor recordThe US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
- The posting doesn’t mention sponsorshipSilence isn’t a refusal — ask the recruiter before investing much time.
- No salary bar for this routeH-1B has no fixed salary bar: the employer must pay at least the prevailing wage for the role and area. Cap-subject employers enter a lottery weighted by wage level. Source: https://www.federalregister.gov/documents/2025/12/29/2025-23853/weighted-selection-process-for-registrants-and-petitioners-seeking-to-file-cap-subject-h-1b, rules effective 2026-02-27.
- What Astrazeneca Pharmaceuticals Lp paid sponsored hires in similar roles15 certified filings for “Associate Director Oncology Outcomes Research” (Medical Scientists, Except Epidemiologists) in MD: $126k–$185k, median $140k. Most were filed at wage level II (47%) — 2 lottery entries, ≈31% projected selection odds for cap-subject employers. Source: US Department of Labor LCA disclosure data (Oct 2025 – Jun 2026).
- Confirmed live todayWhen a source last listed this job as open.
US H-1B: cap-subject employers enter a lottery weighted by wage level — Level I gets 1 entry, Level IV gets 4 (DHS projected selection odds ≈15% at Level I to ≈61% at Level IV). Universities and non-profit research employers are cap-exempt. The $100,000 fee for new petitions from abroad is currently blocked by a court order (appeal pending).
A verdict summarises public evidence; it is not legal advice and never a guarantee — the employer and the immigration authority decide. Sign in to factor in where you can already work.
Or apply yourself on the official page →
Sponsor Radar — Astrazeneca Pharmaceuticals Lp
The US Department of Labor certified 99 H-1B/E-3 labor condition applications for this employer between Oct 2025 and Jun 2026 (latest Jun 2026) — the step every H-1B hire needs first. USCIS also records 31 H-1B approvals in FY2023. Source: LCA disclosure data (US Department of Labor (OFLC)).
Past sponsorship or register membership never guarantees sponsorship for this vacancy or for you. Full Sponsor Radar for Astrazeneca Pharmaceuticals Lp →
About the role
What if your next role helped eliminate cancer as a cause of death? At AstraZeneca, our Oncology ambition is unparalleled. We’ve built and strategically acquired one of the most promising pipelines in the industry, driven by a bold vision to push the boundaries of science, change the practice of medicine, and ultimately eliminate cancer as a cause of death. You will be among inspiring oncology industry leaders who will empower you to be the best, joining teams with a shared sense of urgency to cure cancer and transform patients’ lives. The Executive Director, Search & Evaluation, Oncology R&D, reports to the Vice President Head of Business Development in Oncology R&D at AstraZeneca, with accountability for end-to-end deal-making opportunities across the lifecycle, and has a direct impact on the success of the Oncology R&D strategy and portfolio. This is a senior strategic leadership role at the heart of AstraZeneca’s Oncology R&D ambition. The Executive Director, Search & Evaluation, Oncology R&D proactively scouts external innovation to augment AstraZeneca Discovery, Early and Late Oncology R&D. The successful candidate will have a strong R&D scientific and clinical background, proven project and people leadership, business and strategic acuity and interpersonal skills. In addition, the ability to engage and collaborate across organizational boundaries with an entrepreneurial demeanour by acting with urgency and agility. Key accountabilities • Lead the scientific and strategic aspects of business development opportunities from initial engagement through diligence, governance, negotiation and execution, maintaining momentum and accountability throughout. • Act as a senior scientific partner to external organisations and transaction teams , shaping deal structures and terms that reflect the opportunity’s risks, value inflection points and intended development strategy. • Maintain a strong external network and market perspective across academia, biotechnology, pharmaceuticals, venture capital and the wider oncology ecosystem, using emerging science, competitor intelligence and industry trends to inform portfolio decisions. • Translate external developments into actionable recommendations for Oncology R&D, clearly articulating potential patient benefit, strategic fit, opportunity, risk and value. • Lead appropriately scaled, cross-functional evaluations of external opportunities, integrating scientific, clinical, competitive, operational, commercial, financial, regulatory, legal and manufacturing considerations • Develop clear, executive-ready assessments and business cases for senior leadership and governance bodies, enabling sound prioritisation of opportunities that strengthen the Oncology portfolio. • Communicate complex scientific, strategic and transaction matters with clarity and influence , building trusted relationships with senior stakeholders across the Oncology therapy area, Business Development, Corporate Development and other key functions. • Role model and co-coach S&E colleagues and cross-functional contributors , promoting high standards of scientific rigour, collaboration, pace, inclusion and sound business judgement, and supporting effective transition to post-deal teams. Essential qualifications and experience • Advanced scientific or clinical qualification relevant to oncology, (BSc or above) with at least 10 years of relevant experience . • Deep expertise in oncology biology, drug discovery and clinical development , with the ability to assess opportunities across disease areas, modalities and development stages. • Extensive pharmaceutical or biotechnology business development experience , including identifying, evaluating, diligencing, structuring, negotiating and progressing complex tran